XML 5 R1.htm IDEA: XBRL DOCUMENT v3.25.2
Cover Page
Aug. 25, 2025
Document Information [Line Items]  
Security Exchange Name NASDAQ
Amendment Flag true
Entity Central Index Key 0001369568
Document Type 8-K/A
Document Period End Date Aug. 25, 2025
Entity Registrant Name CATALYST PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-33057
Entity Tax Identification Number 76-0837053
Entity Address, Address Line One 355 Alhambra Circle
Entity Address, Address Line Two Suite 801
Entity Address, City or Town Coral Gables
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33134
City Area Code 305
Local Phone Number 420-3200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CPRX
Entity Emerging Growth Company false
Amendment Description On August 25, 2025, Catalyst Pharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) with the U.S. Securities and Exchange Commission reporting that the Company had entered into a settlement agreement with Lupin Pharmaceuticals, Inc. and Lupin Ltd. (“Lupin”) resolving certain patent litigation brought by the Company and SERB S.A. against Lupin. Since the Company disseminated its press release reporting on the settlement with Lupin, the Company has become aware that the Original 8-K and the press release that was an exhibit to the Original 8-K (the “Original Press Release”) inadvertently misidentified one of the parties that had previously settled patent litigation with the Company and SERB S.A. relating to the Company’s FIRDAPSE® patents. The party that previously settled its litigation with the Company and SERB S.A. relating to the Company’s FIRDAPSE® patents is Inventia Healthcare Limited and not Inventia Life Science Pty Ltd. On August 26, 2025, the Company reissued the Original Press Release to update the identity of the party that previously settled the litigation with the Company and SERB S.A. relating to the Company’s FIRDAPSE® patents. Other than a change to correct the identity of the previous settling party, no other changes were made to the Original Press Release that was disseminated on August 25, 2025. The updated press release that was disseminated on August 26, 2025 is attached to this Form 8-K/A as Exhibit 99.1 and is incorporated herein by reference.